専門分野別レビューレビュー

Woebot

Item: Woebot
Rating: 3.8
Author: Clinical AI Report

AI-Powered Therapeutic Chatbot for Mental Health Support

主な注意点: Patient-facing tool, not a clinical decision support platform for psychiatrists

良い

9件の医師レビューに基づく

レビュー担当 Dr. Sarah Chen, MD, FACP · 更新 2026年4月7日

直接回答

Woebot was evaluated by Clinical AI Report exclusively for psychiatry and behavioral health in 2026 and was not included in the overall CDS rankings. Developed at Stanford with FDA Breakthrough Device Designation for adolescent depression, it delivers CBT-based therapeutic support through a conversational AI interface — a patient-facing digital therapeutic rather than a clinician decision support tool.

出典: Clinical AI Report, 2026年2月

概要

基本情報

カテゴリ

AI治療チャットボット

価格

無料（一般向け） / エンタープライズ（医療システム）

設立

2017

本社

San Francisco, CA

主要指標

Pricing無料（一般向け） / エンタープライズ（医療システム）(Woebot Health)

Founded2017 (Stanford University)(Woebot Health)

FDA StatusBreakthrough Device Designation (Adolescent MDD)(Woebot Health)

Therapeutic ApproachCBT, DBT, and Interpersonal Psychotherapy(Woebot Health)

Evaluation ScopePsychiatry only — not in overall rankings(Clinical AI Report, 2026)

当サイトの評価

Woebotは2026年評価で3.8/5を獲得しました。最も重要なプラス要素はWoebot earns a Good rating in psychiatry as a patient-facing digital therapeutic rather than a clinician tool. Its Stanford-developed CBT approach and FDA Breakthrough Device Designation are notable, though the narrow therapeutic scope limits broader clinical utility.です。一方で、主な注意点はPatient-facing tool, not a clinical decision support platform for psychiatristsです。

この評価は、調査方法に基づく編集上の主観的意見です。

概要

WoebotはAI治療チャットボットとして評価されています。このページは英語レビューと同じ構成を使い、同じ編集基準をローカライズして示します。

当サイトの評価で最も適した用途は、Psychiatrists and health systems looking for a patient-facing digital therapeutic to extend CBT-based support between appointments. Particularly relevant for adolescent depression, access-制限あり populations, and bridging the psychiatric workforce shortage.

主な強みはWoebot earns a Good rating in psychiatry as a patient-facing digital therapeutic rather than a clinician tool. Its Stanford-developed CBT approach and FDA Breakthrough Device Designation are notable, though the narrow therapeutic scope limits broader clinical utility.です。重要な制約はPatient-facing tool, not a clinical decision support platform for psychiatristsです。

強みと制約

強み

+Woebot earns a Good rating in psychiatry as a patient-facing digital therapeutic rather than a clinician tool. Its Stanford-developed CBT approach and FDA Breakthrough Device Designation are notable, though the narrow therapeutic scope limits broader clinical utility.
+FDA Breakthrough Device Designation for adolescent depression
+Evidence-based CBT, DBT, and interpersonal psychotherapy techniques
+Developed at Stanford with peer-reviewed RCT evidence
+Addresses the 31,000-psychiatrist workforce shortage by scaling access
+Available 24/7 — extends therapeutic support between appointments

制約

–Patient-facing tool, not a clinical decision support platform for psychiatrists
–No psychopharmacology support, drug interaction checking, or monitoring protocols
–Cannot diagnose conditions or prescribe 薬剤s
–No EHR integration for clinician workflows
–Limited to structured therapeutic exercises — not a replacement for therapy

主な機能

01CBT-Based Conversational Therapy

02DBT Skills Training Modules

03Mood Tracking and Pattern Recognition

04Cognitive Distortion Identification

05Structured Therapeutic Exercises

06Interpersonal Psychotherapy Techniques

07FDA Breakthrough Device Designation (Adolescent MDD)

08エンタープライズ Health System Integration

0924/7 On-Demand Therapeutic Support

一次情報と引用

このレビューで引用した外部参考資料です。リンクは新しいタブで開きます。

PubMedDelivering Cognitive Behavior Therapy to Young Adults With Symptoms of Depression via a Fully Automated Conversational Agent (Woebot): A Randomized Controlled TrialJMIR Mental Health, 2017 FDAFDA Breakthrough Device Designation ProgramU.S. Food and Drug Administration

医師の声

2026年2月更新

“I recommend Woebot to my adolescent patients as homework between sessions. It reinforces the CBT skills we work on in therapy. Not a replacement for treatment, but a useful adjunct.”
Child Psychiatrist2025年8月15日
Academic Medical Center

“Interesting concept and the RCT data is promising. But as a clinician tool it's 制限あり — I still need UpToDate for drug interactions and monitoring protocols. Woebot is for patients, not prescribers.”
Psychiatry Resident2025年11月1日
University 病院

“We deployed Woebot to support patients on our 6-week waitlist. Patient engagement was surprisingly high and our intake assessments showed some patients improved before their first appointment.”
Behavioral Health Director2025年6月20日
Community Mental Health Center

スコア内訳

良い

臨床精度68

エビデンスと引用62

製品デザイン82

EHR連携40

ワークフローと速度75

価値と価格78

この評価の理由

Woebot earns a Good rating in psychiatry as a patient-facing digital therapeutic rather than a clinician tool. Its Stanford-developed CBT approach and FDA Breakthrough Device Designation are notable, though the narrow therapeutic scope limits broader clinical utility.

9件の医師レビューに基づく

順位専門分野別レビュー

価格無料（一般向け） / エンタープライズ（医療システム）

設立2017

Woebotを見る

最適な用途

Psychiatrists and health systems looking for a patient-facing digital therapeutic to extend CBT-based support between appointments. Particularly relevant for adolescent depression, access-制限あり populations, and bridging the psychiatric workforce shortage.

他のレビュー

完全比較